Verona Pharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 480
- Registration Number
- NCT07016412
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- Drug: Nebulized Placebo Solution
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 180
- Registration Number
- NCT06559150
- Locations
- 🇺🇸
Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸So Cal Institute for Respiratory Diseases, Inc., Los Angeles, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 46
- Registration Number
- NCT06545500
- Locations
- 🇺🇸
Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida Inc - Tampa, Tampa, Florida, United States
🇺🇸Midwest Chest Consultants PC, Saint Charles, Missouri, United States
Effect of Ensifentrine Treatment on CAT Score
- Conditions
- COPD
- Interventions
- Drug: Ensifentrine 3 mg twice daily
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 20
- Registration Number
- NCT06460493
- Locations
- 🇺🇸
Midwest Chest Consultants, Saint Charles, Missouri, United States
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 50
- Registration Number
- NCT05270525
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 790
- Registration Number
- NCT04542057
- Locations
- 🇺🇸
Wright Clinical Research, LLC, Alabaster, Alabama, United States
🇺🇸SEC Clinical Research, Andalusia, Alabama, United States
🇺🇸Jasper Summit Research LLC, Jasper, Alabama, United States
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 763
- Registration Number
- NCT04535986
- Locations
- 🇺🇸
Phoenix Medical Group, Peoria, Arizona, United States
🇺🇸AMR Tempe, Tempe, Arizona, United States
🇺🇸Beach Physicians Medical Group, Huntington Beach, California, United States
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
- Conditions
- COPD
- Interventions
- Drug: Placebos
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 40
- Registration Number
- NCT04091360
- Locations
- 🇬🇧
Respiratory Clinical Trials Ltd, London, United Kingdom
🇬🇧Medicines Evaluation Unit Limited, Wythenshawe, United Kingdom
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebos
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 37
- Registration Number
- NCT04027439
- Locations
- 🇺🇸
VitaLink Research -- Union, Union, South Carolina, United States
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
- Conditions
- COPD
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 416
- Registration Number
- NCT03937479
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸California Research Medical Group, Inc, Fullerton, California, United States
🇺🇸Southern California Institute For Respiratory Diseases, Inc., Los Angeles, California, United States